Skip to search formSkip to main contentSkip to account menu

anagrelide

Known as: Anagrelida, Anagrelidum, anagrelide [Chemical/Ingredient] 
A synthetic quinazoline derivative, Anagrelide reduces platelet production through a decrease in megakaryocyte maturation. Anagrelide inhibits cyclic… 
National Institutes of Health

Related topics

Related topics

11 relations

Narrower (2)

AgrelinAgrylin
Anagrelide hydrochlorideDrug AllergyPhosphodiesterase 3 Inhibitors [MoA]Polycythemia Vera

Broader (3)

Fibrinolytic AgentsPlatelet Aggregation InhibitorsQuinazolines

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2013
Review
2013
A global view of health--an unfolding series.
This issue of the Journal includes the first article in a series of review articles on global health.1 In a journal that proudly… 
Review
2008
Review
2008
Final Results of the ANAHYDRET-Study: Non-Inferiority of Anagrelide Compared to Hydroxyurea in Newly Diagnosed WHO-Essential Thrombocythemia Patients
Background: Both anagrelide and hydroxyurea effectively lower platelet counts in essential thrombocythemia (ET) and other… 
2007
2007
Essential versus reactive thrombocythemia in children: Retrospective analyses of 12 cases
Essential thrombocythemia (ET) rarely occurs in the pediatric population and little is known about the clinical course and the… 
Highly Cited
2004
Highly Cited
2004
Adverse effects and benefits of two years of anagrelide treatment for thrombocythemia in chronic myeloproliferative disorders.
BACKGROUND AND OBJECTIVES Although anagrelide is widely used in the treatment of thrombocythemia in myeloproliferative diseases… 
Highly Cited
1999
Highly Cited
1999
Bone marrow effects of anagrelide therapy in patients with myelofibrosis with myeloid metaplasia
In a prospective study investigating the therapeutic role of anagrelide in myelofibrosis with myeloid metaplasia, 20 patients… 
Review
1999
Review
1999
Treatment of essential thrombocythemia with anagrelide.
Essential thrombocythemia (ET), the most common of the chronic myeloproliferative disorders, is characterized by thrombotic and… 
Highly Cited
1998
Highly Cited
1998
Anagrelide, a novel platelet lowering option in essential thrombocythaemia: treatment experience in 48 patients in Germany
Abstract: We report on our treatment experience in Germany with anagrelide, a novel platelet lowering agent, in 48 patients (27… 
1998
1998
Anagrelide for treatment of patients with chronic myelogenous leukemia and a high platelet count.
Chronic myelogenous leukemia (CML) is usually treated with hydroxyurea or interferon-alpha. In some patients high platelet counts… 
Highly Cited
1983
Highly Cited
1983
Microscopic measurements of platelet aggregation reveal a low ADP-dependent process distinct from turbidometrically measured aggregation.
Platelet aggregation measured from the decrease in the number of nonaggregated platelets (PA) is compared with that measured from… 
1982
1982
Effect of thromboxane synthetase inhibitors on platelet function: enhancement by inhibition of phosphodiesterase.
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)